An observational study in Esophageal Cancer, Esophageal Neoplasms and Gastric Cancer, sponsored by Region Skane. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Region Skane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Esophageal Neoplasms with a site in Sweden — 8 open to participants now, 8 under way, 1 of them phase 3. Esophageal Neoplasms · Sweden.
Among the 30 studies in Esophageal Neoplasms with a site in Sweden, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2023, is one of 11 observational ones, and was the 26th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →8 of the 30 studies in Esophageal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
University Hospital, Antwerp · Sites in Sweden, Belgium, Denmark and 3 more countries
Ages 18+
Karolinska University Hospital · Sites in Sweden
Ages 18+
National University Hospital, Singapore · Sites in Sweden, Germany, Japan and 3 more countries
Ages 21+
Universitaire Ziekenhuizen KU Leuven · Sites in Sweden, United States, Belgium and 3 more countries
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Sweden, United States, Brazil and 11 more countries
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 80 across the 19 interventional studies, 1,000 across the 11 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 30 have an industry lead sponsor. The 10 most frequent:
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Region Skane has 3 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Esophageal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06115629Phase 3University of Dublin, Trinity CollegeSurveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Esophageal Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.
Sweden has had a National Cancer Rehabilitation Programme since 2014. This emphasises that all people with cancer have the right to individualised rehabilitation and that the contact nurse has an important role to play in identifying needs and ensuring evidence-based interventions throughout the cancer process to promote rehabilitation. The needs for optimised rehabilitation vary according to several parameters such as the person's personal circumstances and preferences, social support and type of cancer disease.
Despite this and a growing number evidence within this area cancer rehabilitation is often not integrated in clinical care. The current cancer care focuses on medical and treatment related interventions. It is a challenge for health services to find models to identify and meet the increased need for cancer rehabilitation in a systematic and structured way throughout the cancer process, based on the specific needs of each individual. This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.
*patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden (Skåne), and are planned to undergo or has undergone curative surgerytreatment at Skåne University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden, and who are planned to undergo curative surgery treatment at Skåne University Hospital. n=100 (anticipated)
Other: evidence-based individualized rehabilitation
The historical control group consists of patients, living in Southern Sweden, who underwent esophageal or gastric cancer surgery between 2013 - 2021 at Skåne University Hospital. n=100 (anticipated)
The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
General Quality of life
The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
General Quality of life
The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
General Quality of life
The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
General Quality of life
The instrument QLQ-C30 is developed by the EORTC (European Organization for Research and Treatment of Cancer) and measures quality of life. The instrument has a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit 4=very much). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures in score from 0-100. A high scale score represents a higher response level. A high score for functional scale represents a high/healthy level of functioning. A high score for global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Esophageal and gastric cancer specific Quality of life
The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Esophageal and gastric cancer specific Quality of life
The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Esophageal and gastric cancer specific Quality of life
The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
Esophageal and gastric cancer specific Quality of life
The instrument QLQ-OG25 is developed by the EORTC and measures diagnose specific quality of life. The instrument hast a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scoring approach for this instrument is identical in principle to that used for the scales/items of the EORTC-QLQ-C30.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Information needs
The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Information needs
The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Information needs
The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
Information needs
The INFO-26 instrument is developed by the EORTC and measures the patients perception of information received. The response format is a four-point Likert scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) in all items except four which has a two point scale (Yes/No).
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
International Physical Activity Questionnaire
The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
International Physical Activity Questionnaire
The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
International Physical Activity Questionnaire
The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
International Physical Activity Questionnaire
The instrument IPAQ will be used to measure physical activity trough 5 questions on level of physical activity and time spent on physical activity. The IPAQ short form asks about three specific types of activities which are assessed in walking, moderate-intensity activities and vigorous-intensity activities. The instrument provides separate scores (duration and frequency) on the three types of activity.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Hospital Anxiety and Depression Scale
HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Hospital Anxiety and Depression Scale
HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Hospital Anxiety and Depression Scale
HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
Hospital Anxiety and Depression Scale
HADS will be used to measure the patients level of anxiety and depression. HADS is a 14-item scale with items for anxiety and depression subscales. Each item is rated on a 4-point Likert scale (ranging from 0=not at all, to 3=yes definitely) for a total score from 0-21 for each subscale. A higher score indicates higher levels of anxiety or depression.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Assessment of Survivorship Concerns
ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Assessment of Survivorship Concerns
ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Assessment of Survivorship Concerns
ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
Assessment of Survivorship Concerns
ASC will be used to measure the patients worry about cancer and worry about health trough 5 questions ranging from 1-4. Higher scores indicates greater worry.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Resilience
Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Resilience
Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Resilience
Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.
Time frame: Instrument will be answered by the patientafter surgery at 6 months postoperative
Resilience
Connor-Davidsson Resilience Scale (CD-RISC) will be used to measure patients resilience trough 10 questions ranging from 0-4 Lower scores indicate more problems.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Assessment of rehabilitation needs.
Assessment of rehabilitation needs will be used to measure patients rehabilitation needs. A 4 point Likert scale which ranges from "no problem" to "very troublesome problem" . Higher scores indicate more problems.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Assessment of rehabilitation needs.
Higher scores indicate more problems.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative
Assessment of rehabilitation needs.
Higher scores indicate more problems.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative
Assessment of rehabilitation needs.
Higher scores indicate more problems.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative
Psychological Distress
Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision)
Psychological Distress
Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.
Psychological Distress
Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.
Psychological Distress
Psychological Distress is measured by the "Distress thermometer" and will be used to measure level of distress. A scale from 0 = no distress to 10 = high distress. Higher scores indicate greater distress.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
Sickness absence/work
Sickness abscens and to which extent the patient work will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision).
Sickness absence/work
Sickness abscens and to which extent the patient work will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.
Sickness absence/work
Sickness abscens and to which extent the patient work will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.
Sickness absence/work
Sickness abscens and to which extent the patient work will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
Physical activity
Single item question concerning amount of hours physical activity per day.
Time frame: Single item question will be answered by the patient at baseline (at treatment decision).
Physical activity
Single item question concerning amount of hours physical activity per day.
Time frame: Single item question will be answered by the patient at approximately 1 week preoperative.
Physical activity
Single item question concerning amount of hours physical activity per day.
Time frame: Single item question will be answered by the patient after surgery at 6 months postoperative.
Physical activity
Single item question concerning amount of hours physical activity per day.
Time frame: Single item question will be answered by the patient after surgery at 12 months postoperative.
Alcohol use
Single item questions concerning alcohol use.
Time frame: Single item questions will be answered by the patient at baseline (at treatment decision).
Alcohol use
Single item questions concerning alcohol use.
Time frame: Single item questions will be answered by the patient at approximately 1 week preoperative.
Alcohol use
Single item questions concerning alcohol use.
Time frame: Single item questions will be answered by the patient after surgery at 6 months postoperative.
Alcohol use
Single item questions concerning alcohol use.
Time frame: Single item questions will be answered by the patient after surgery at 12 months postoperative.
Tobacco use
Single item questions concerning tobacco use.
Time frame: Single item questions will be answered by the patient at baseline (at treatment decision).
Tobacco use
Single item questions concerning tobacco use.
Time frame: Single item questions will be answered by the patient at approximately 1 week preoperative.
Tobacco use
Single item questions concerning tobacco use.
Time frame: Single item questions will be answered by the patient after surgery at 6 months postoperative.
Tobacco use
Single item questions concerning tobacco use.
Time frame: Single item questions will be answered by the patient after surgery at 12 months postoperative.
Height
Single item question concerning height in meters.
Time frame: Single item question will be answered by the patient at baseline (at treatment decision).
Weight
Single item question concerning weight in kilograms.
Time frame: Single item question will be answered by the patient at baseline (at treatment decision).
Weight
Single item question concerning weight in kilograms.
Time frame: Single item question will be answered by the patient at approximately 1 week preoperative.
Weight
Single item question concerning weight in kilograms.
Time frame: Single item question will be answered by the patient after surgery at 6 months postoperative.
Weight
Single item question concerning weight in kilograms.
Time frame: Single item question will be answered by the patient after surgery at 12 months postoperative.
Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: Instrument will be answered by the patient after surgery at baseline (at treatment decision).
Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.
Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.
Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
Dysphagia
Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision).
Dysphagia
Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.
Dysphagia
Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.
Dysphagia
Dysphagia will be measured by a single item concerning how it works to swallow for the patient and it ranges from 0-4 (0=no dysphagia to 4=total dysphagia) Higher scores indicate more difficulties swallowing.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
Rehabilitation process
Questions about the rehabilitation process will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient at baseline (at treatment decision).
Rehabilitation process
Questions about the rehabilitation process will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient at approximately 1 week preoperative.
Rehabilitation process
Questions about the rehabilitation process will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient after surgery at 6 months postoperative.
Rehabilitation process
Questions about the rehabilitation process will be measured by single items concerning this area.
Time frame: Instrument will be answered by the patient after surgery at 12 months postoperative.
Demographics
Demographic details will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). There are no scales, only quality registry data.This data includes gender,cancerdiagnosis, tumourstage, comorbidity according to ASA, surgerydate, postoperative tumourstage.
Time frame: The data will be collected 12 months after surgery.
Overall survival
Overall survival will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). There are no scales, only quality registry data.
Time frame: Up to 1 year after surgery
Incidence and severity of general complications
Incidence rate and severity of general complication according to Clavien-Dindo classification. Genereal complications will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer).
Time frame: Up to 30 days postoperative
Change of level of care
Incidence rate of change of level of care in the context of postoperative care will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer).
Time frame: Up to 30 days postoperative
Length of stay
Length of stay at the hospital will be collected from participants via NREV (Swedish national quality registry for esophageal and gastric cancer). Will be measured in number of days.
Time frame: from the day before surgery to discharge from the hospital
Rate of re-admission
The rate of re-admission up to 30 days postoperative will be collected via NREV (Swedish national quality registry for esophageal and gastric cancer).
Time frame: Up to 30 days postoperative
Discharge destination
Postoperative discharge destination (i.e if the patients goes home or to another care unit after discharge) will be collected via NREV (Swedish national quality registry for esophageal and gastric cancer)
Time frame: The data will be collected 12 months postoperative
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.
Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 58 months is below that.
Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.